Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen

T-cell recognition of Lol p 9, a major allergen of ryegrass pollen, was investigated by using a T-cell line and T-cell clones generated from the peripheral blood of an atopic donor. The T- cell line reacted with purified Lol p 9, as well as with crude ryegrass pollen extract, but failed to cross-rea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 1996-07, Vol.98 (1), p.124-132
Hauptverfasser: Blaher, Bella, Suphioglu, Cenk, Knox, R.Bruce, Singh, Mohan B., McCluskey, James, Rolland, Jennifer M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:T-cell recognition of Lol p 9, a major allergen of ryegrass pollen, was investigated by using a T-cell line and T-cell clones generated from the peripheral blood of an atopic donor. The T- cell line reacted with purified Lol p 9, as well as with crude ryegrass pollen extract, but failed to cross-react with Bermuda grass pollen extract. All of six T-cell clones generated from this line proliferated in response to Lol p 9. Epitope mapping was carried out with a panel of 34 overlapping synthetic peptides, which spanned the entire sequence of the Lol p 9 12R isoform. The T-cell line responded to two of the peptides, Lol p 9 (105-116) and Lol p 9 (193-204), whereas reactivity with one or other of these peptides was shown by five T-cell clones. These two peptides contained sequences consistent with motifs previously reported for major histocompatibility complex class II–restricted peptides. HLA antibody blocking studies showed that presentation of peptide Lol p 9 (105-116) to one T-cell clone was HLA-DR–restricted; this clone expressed a T helper cell phenotype (CD3 +, CD4 +) and the T-cell receptor αb. The identification of immunodominant T-cell epitope(s) on allergens is essential for devising safer and more effective immunotherapy strategies, which can interrupt the chain of events leading to allergic disease. (J A LLERGY C LIN I MMUNOL 1996;98:124-32.)
ISSN:0091-6749
1097-6825
DOI:10.1016/S0091-6749(96)70234-8